Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease

Hybrids based on an aza-analogue of CGP37157, a mitochondrial Na+/Ca2+ exchanger antagonist, and lipoic acid were obtained in order to combine in a single molecule the antioxidant and NRF2 induction properties of lipoic acid and the neuroprotective activity of CGP37157. The four possible enantiomers...

Descripción completa

Detalles Bibliográficos
Autores: Cores Esperón, Ángel, Michalska Dziama, Patrycja, Pérez Moreno, José Miguel, Crisman Vigil, Enrique, Gómez Serrano, Clara, Villacampa Sanz, Mercedes, Menéndez Ramos, José Carlos, León Martínez, Rafael
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/72079
Acceso en línea:https://hdl.handle.net/20.500.14352/72079
Access Level:acceso abierto
Palabra clave:CGP37157
lipoic acid
neuroprotection
NRF2 induction
Neurociencias (Medicina)
Química farmaceútica
2490 Neurociencias
2390 Química Farmacéutica
id ES_ea48b608c5123eeaee2e0809f60b8703
oai_identifier_str oai:docta.ucm.es:20.500.14352/72079
network_acronym_str ES
network_name_str España
repository_id_str
spelling Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s DiseaseCores Esperón, ÁngelMichalska Dziama, PatrycjaPérez Moreno, José MiguelCrisman Vigil, EnriqueGómez Serrano, ClaraVillacampa Sanz, MercedesMenéndez Ramos, José CarlosLeón Martínez, RafaelCGP37157lipoic acidneuroprotectionNRF2 inductionNeurociencias (Medicina)Química farmaceútica2490 Neurociencias2390 Química FarmacéuticaHybrids based on an aza-analogue of CGP37157, a mitochondrial Na+/Ca2+ exchanger antagonist, and lipoic acid were obtained in order to combine in a single molecule the antioxidant and NRF2 induction properties of lipoic acid and the neuroprotective activity of CGP37157. The four possible enantiomers of the hybrid structure were synthesized by using as the key step a fully diastereoselective reduction induced by Ellman’s chiral auxiliary. After computational druggability studies that predicted good ADME profiles and blood–brain permeation for all compounds, the DPPH assay showed moderate oxidant scavenger capacity. Following a cytotoxicity evaluation that proved the compounds to be non-neurotoxic at the concentrations tested, they were assayed for NRF2 induction capacity and for anti-inflammatory properties and measured by their ability to inhibit nitrite production in the lipopolysaccharide-stimulated BV2 microglial cell model. Moreover, the compounds were studied for their neuroprotective effect in a model of oxidative stress achieved by treatment of SH-SY5Y neuroblastoma cells with the rotenone–oligomycin combination and also in a model of hyperphosphorylation induced by treatment with okadaic acid. The stereocenter configuration showed a critical influence in NRF2 induction properties, and also in the neuroprotection against oxidative stress experiment, leading to the identification of the compound with S and R configuration as an interesting hit with a good neuroprotective profile against oxidative stress and hyperphosphorylation, together with a relevant anti-neuroinflammatory activity. This interesting multitarget profile will be further characterized in future work.MPDIUniversidad Complutense de Madrid20222022-01-0420222022-01-04journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/72079reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)InglésengRTI2018-097662-B-I00 Not available Not availablePI17 01700 Not availablePI20 00433B2017 BMD-3813PI20 00433 Not availablePI20 00433B2017 BMD-3827open accesshttp://purl.org/coar/access_right/c_abf2Atributtion 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/720792026-06-02T12:44:21Z
dc.title.none.fl_str_mv Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease
title Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease
spellingShingle Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease
Cores Esperón, Ángel
CGP37157
lipoic acid
neuroprotection
NRF2 induction
Neurociencias (Medicina)
Química farmaceútica
2490 Neurociencias
2390 Química Farmacéutica
title_short Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease
title_full Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease
title_fullStr Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease
title_full_unstemmed Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease
title_sort Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease
dc.creator.none.fl_str_mv Cores Esperón, Ángel
Michalska Dziama, Patrycja
Pérez Moreno, José Miguel
Crisman Vigil, Enrique
Gómez Serrano, Clara
Villacampa Sanz, Mercedes
Menéndez Ramos, José Carlos
León Martínez, Rafael
author Cores Esperón, Ángel
author_facet Cores Esperón, Ángel
Michalska Dziama, Patrycja
Pérez Moreno, José Miguel
Crisman Vigil, Enrique
Gómez Serrano, Clara
Villacampa Sanz, Mercedes
Menéndez Ramos, José Carlos
León Martínez, Rafael
author_role author
author2 Michalska Dziama, Patrycja
Pérez Moreno, José Miguel
Crisman Vigil, Enrique
Gómez Serrano, Clara
Villacampa Sanz, Mercedes
Menéndez Ramos, José Carlos
León Martínez, Rafael
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad Complutense de Madrid
dc.subject.none.fl_str_mv CGP37157
lipoic acid
neuroprotection
NRF2 induction
Neurociencias (Medicina)
Química farmaceútica
2490 Neurociencias
2390 Química Farmacéutica
topic CGP37157
lipoic acid
neuroprotection
NRF2 induction
Neurociencias (Medicina)
Química farmaceútica
2490 Neurociencias
2390 Química Farmacéutica
description Hybrids based on an aza-analogue of CGP37157, a mitochondrial Na+/Ca2+ exchanger antagonist, and lipoic acid were obtained in order to combine in a single molecule the antioxidant and NRF2 induction properties of lipoic acid and the neuroprotective activity of CGP37157. The four possible enantiomers of the hybrid structure were synthesized by using as the key step a fully diastereoselective reduction induced by Ellman’s chiral auxiliary. After computational druggability studies that predicted good ADME profiles and blood–brain permeation for all compounds, the DPPH assay showed moderate oxidant scavenger capacity. Following a cytotoxicity evaluation that proved the compounds to be non-neurotoxic at the concentrations tested, they were assayed for NRF2 induction capacity and for anti-inflammatory properties and measured by their ability to inhibit nitrite production in the lipopolysaccharide-stimulated BV2 microglial cell model. Moreover, the compounds were studied for their neuroprotective effect in a model of oxidative stress achieved by treatment of SH-SY5Y neuroblastoma cells with the rotenone–oligomycin combination and also in a model of hyperphosphorylation induced by treatment with okadaic acid. The stereocenter configuration showed a critical influence in NRF2 induction properties, and also in the neuroprotection against oxidative stress experiment, leading to the identification of the compound with S and R configuration as an interesting hit with a good neuroprotective profile against oxidative stress and hyperphosphorylation, together with a relevant anti-neuroinflammatory activity. This interesting multitarget profile will be further characterized in future work.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-01-04
2022
2022-01-04
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/72079
url https://hdl.handle.net/20.500.14352/72079
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv RTI2018-097662-B-I00 Not available Not available
PI17 01700 Not available
PI20 00433B2017 BMD-3813
PI20 00433 Not available
PI20 00433B2017 BMD-3827
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atributtion 4.0 International
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atributtion 4.0 International
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MPDI
publisher.none.fl_str_mv MPDI
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423127010738176
score 15,301603